A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

May 31, 2016

Study Completion Date

March 31, 2017

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Allogeneic Mesenchymal Precursor Cells

DRUG

Normal Saline

Trial Locations (23)

2050

Royal Prince Alfred Hospital, Camperdown

3145

Emeritus Research, Malvern

7000

Southern Clinical Research Pty Ltd, Hobart

15261

University of Pittsburgh, Pittsburgh

21224

JHU Arthritis Center Baltimore, Baltimore

21702

Arthritis Treatment Center, Frederick

28210

DJL Clinical Research, Charlotte

33614

McIlwain Medical Group, Tampa

34239

Sarasota Arthritis Research Center, Sarasota

34474

Ocala Rheumatology Research Center, Ocala

34684

Arthritis Center, Palm Harbor

36207

Pinnacle Research Group, Anniston

38305

West Tennessee Research Institute, Jackson

55905

Mayo Clinic, Rochester

73102

Health Research of Oklahoma, Oklahoma City

77034

Accurate Clinical Research, Houston

78217

Texas Arthritis Research Center, San Antonio

85234

Arthrocare Arthritis Care and Research PC, Gilbert

90025

UCLA, Los Angeles

91786

Inland Rheumatology Clinical Trials Incorporated, Upland

92020

Triwest Research Associates, El Cajon

01605

Reliant Medical Group, Worcester

07410

Office of Ramesh C. Gupta, MD, Fair Lawn

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

PPD Development, LP

INDUSTRY

lead

Mesoblast, Ltd.

INDUSTRY